Poxel SA POXEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €0.60
- Day Range
- €0.54–0.60
- 52-Week Range
- €0.30–0.95
- Bid/Ask
- €0.54 / €0.55
- Market Cap
- €21.12 Mil
- Volume/Avg
- 225,985 / 337,712
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 37
- Website
- https://www.poxel.com
Valuation
|
Metric
|
POXEL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
POXEL
Financial Strength
|
Metric
|
POXEL
|
|---|---|
Quick Ratio | 0.58 |
Current Ratio | 0.60 |
Interest Coverage | −7.25 |
Quick Ratio
POXEL
Profitability
|
Metric
|
POXEL
|
|---|---|
Return on Assets (Normalized) | −59.06% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −68.30% |
Return on Assets
POXEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Phdfxfzlk | Glyzgq | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Szrhffd | Xxtkbjq | $114.2 Bil | |||
| Moderna Inc
MRNA
| Kjxnnxw | Rql | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Pgphlldv | Nqmw | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ttpyqwn | Wwzp | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ggpwmqft | Rcndjd | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rdrxrnvvx | Llmmdh | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Plcwpvkjz | Crzyy | $12.8 Bil | |||
| Incyte Corp
INCY
| Rrmvkwshh | Fjhfw | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Frlyfwxd | Ftqcz | $12.2 Bil |